Oncology test kit GENESEEQPRIME™

for cancersfor genomicsfor precision medicine

A comprehensive genomic profiling panel across all solid tumors GeneseeqPrime™ analyzes 437 cancer-related genes by next-generation sequencing. It reveals clinically actionable information for therapy selection by providing valuable insight into key oncogenic genes and drug resistance mechanisms. WHO IS IT FOR Patients with solid tumors seeking precision medicine SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others) All-in-one test for 437 cancer-related genes Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR) Assesses key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes GeneseeqPrime™ Report 1 Provides information on clinically actionable genomic alterations and their associated targeted therapy, both approved drugs and those in clinical trials 2 Evaluates TMB and MSI to better inform immunotherapy decisions 3 Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers 4 Reveals potential resistance mechanisms to current therapies and options for alternative treatments 5 Assesses genetic predisposition to certain cancer types for early intervention